Cargando…
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
Inhibition of dipeptidyl peptidase-4 (DPP-4) as a novel therapy for type 2 diabetes is based on prevention of the inactivation process of bioactive peptides, the most important in the context of treatment of diabetes of which is glucagon-like peptide-1(GLP-1). Most clinical experience with DPP-4 inh...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2496991/ https://www.ncbi.nlm.nih.gov/pubmed/18561513 |